These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22154617)

  • 1. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
    Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
    Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer.
    Goto I; Yoneda S; Yamamoto M; Kawajiri K
    Cancer Res; 1996 Aug; 56(16):3725-30. PubMed ID: 8706015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms.
    Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
    Oncol Rep; 2004 Oct; 12(4):773-9. PubMed ID: 15375499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
    Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
    Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.
    Kawajiri K; Eguchi H; Nakachi K; Sekiya T; Yamamoto M
    Cancer Res; 1996 Jan; 56(1):72-6. PubMed ID: 8548778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
    Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CYP1A1 polymorphisms, lack of glutathione S-transferase M1 (GSTM1), cooking oil fumes and lung cancer risk in non-smoking women].
    Zhu XX; Hu CP; Gu QH
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Nov; 33(11):817-22. PubMed ID: 21211368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
    Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Oncogene; 2001 Mar; 20(14):1765-70. PubMed ID: 11313923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung.
    Larsen JE; Colosimo ML; Yang IA; Bowman R; Zimmerman PV; Fong KM
    Carcinogenesis; 2006 Mar; 27(3):525-32. PubMed ID: 16195240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer.
    Wang YC; Chen CY; Wang HJ; Chen SK; Chang YY; Lin P
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):402-10. PubMed ID: 10418172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutation, allelism and survival in non-small cell lung cancer.
    Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
    Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
    Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
    Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.